Mesenchymal stem cells (MSCs) bioprinting offers a new opportunity for critical-size bone regeneration. MSCs have emerged as a key cell source for tissue engineering due to their potential for differentiation. Additionally, MSCs promote neoangiogenesis, exert immunoregulatory and anti-inflammatory effects, and regulate overall tissue repair through the secretion of growth factors.
GelXA Bone and CELLINK Bone bioinks mixed with 10 million MSCs/ml were printed using BioX (CELLINK). Cell survival and proliferation were measured. Alkaline phosphatase (ALP) activity and gene expression of ALP, RUNX2 and osteocalcin (OCN) were followed to assess the osteogenic differentiation in vitro. For in vivo bone regeneration, prints were transplanted into mouse calvarial defects. New bone formation was assessed by micro-CT and confirmed by histology.
MSCs successfully proliferated and differentiated in both bioinks, but the dynamics of osteogenic markers expression were opposite. In CELLINK-MSC prints, ALP activity increased over time, while in GelXA-MSC prints, ALP activity and mRNA expression peaked at day 7 and subsequently decreased. RT-PCR of CELLINK-MSC revealed low RUNX2 and no OCN. Conversely, RUNX2 expression increased over time, and OCN was detectable on D21 in GelXA-MSC prints. Six weeks after transplantation of prints, micro-CT analysis of mice calvaria revealed significant new bone formation in the CELLINK-MSC group and lower in the GelXA-MSC group.
This study demonstrates contrasting results for the osteogenic differentiation of GelXA and CELLINK MSC bioprints in vitro and in vivo. GelXA-MSC prints showed higher osteogenic marker expression in vitro compared to CELLINK-MSC prints, while the CELLINK-MSC group exhibited greater new bone formation in vivo. Indirectly, this is an indication of the role of MSCs in bone repairment in vivo – regulation of the regeneration process seems to be more important than their direct differentiation.